MedTrace Logo

Basal Plus GLP1-ra on Glycemic Variability in CKD

NCT05218915 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2024-12-03

No results posted yet for this study

Summary

To compare GLP-1 RA plus basal insulin (BGLP) versus basal-bolus (BB) insulin regimens on glycemic variability (GV) and time in range (TIR) in diabetes patients CKD stage 3-4

Conditions

Interventions

DRUG

Dulaglutide

Dulaglutide once weekly subcutaneous

DRUG

Insulin Degludec

Insulin degludec once daily

DEVICE

Continuous glucose monitor

Dexcom G6 CGM system

Sponsors & Collaborators

  • Elaine Chow

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-28
Primary Completion
2024-10-30
Completion
2024-10-30
FDA Device
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05218915 on ClinicalTrials.gov